xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts October 30, 2009 : CELG, SNSS, GPOR and ARYX

Xtremepicks.com Alerts include Celgene Corporation (NASDAQ: CELG), Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), Gulfport Energy Corporation (Nasdaq: GPOR) and ARYx Therapeutics, Inc. (NASDAQ: ARYX)

Celgene Corporation (NASDAQ: CELG) trading at $51.37 on a volume of 2.08M shares

In a press release out on October 30, Celgene Corporation to Present at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference

SUMMIT, N.J., Oct 30, 2009 -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) trading at $0.39 per share on trading volume of 95,321 shares.

In a press release out on October 30, Sunesis Completes Enrollment of Voreloxin REVEAL-1 Trial in Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Oct 30, 2009 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

Gulfport Energy Corporation (Nasdaq:GPOR) trading at $7.57 on a volume of 103,596 shares

In a press release out on October 30, Gulfport Energy Corporation Schedules Third Quarter 2009 Financial and Operational Results Conference Call

OKLAHOMA CITY, Oct 30, 2009 -- Gulfport Energy Corporation (Nasdaq:GPOR) will hold a conference call on Thursday, November 5, 2009 at 1:00 p.m. CST to discuss its third quarter 2009 financial and operational results. The call will follow the release of Gulfport's third quarter 2009 earnings the morning of November 5, 2009.

About Gulfport

Gulfport Energy Corporation is an Oklahoma City-based independent oil and natural gas exploration and production company with its principal producing properties located along the Louisiana Gulf Coast and the Permian Basin in West Texas. Gulfport also holds a sizeable acreage position in the Alberta Oil Sands in Canada through its interest in Grizzly Oil Sands ULC.

ARYx Therapeutics, Inc. (NASDAQ:ARYX) trading at $2.29 on a volume of 22,306 shares

In a press release out on October 30, ARYx to Present at the Oppenheimer Annual Healthcare Conference

FREMONT, Calif., Oct 30, 2009 -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 4, 2009 at 10:15 am Eastern. A live Webcast of the presentation, together with the presentation slides, may be accessed at the ARYx Website http://www.aryx.com. The presentation will be archived for 30 days following the presentation.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit the ARYx Website atwww.aryx.com for additional information.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: california, canada, cancer, clinical, conference, drugs, earnings, elderly, email, e-mail, energy, exploration, investment, investment opinion, nasdaq, natural gas, new york, new jersey, oil, oklahoma, pharmaceuticals, products, profit, technology, trial, web